600521.SH
华海药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 16.20
−2.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.6B | 8.6B | 9.5B | 8.3B | 8.3B |
| Cost of Revenue | 3.6B | 3.4B | 3.6B | 3.3B | 3.1B |
| Gross Profit | 5.0B | 5.2B | 5.9B | 5.0B | 5.2B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 1.2B | 986.7M | 983.0M | 925.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.6B | 1.6B | 1.5B | 1.3B | 1.3B |
| Selling & Marketing Expense | 1.5B | 1.6B | 1.7B | 1.3B | 1.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 4.7B | 4.7B | 4.3B | 3.8B | 3.5B |
| Cost and Expenses | 8.3B | 8.1B | 8.0B | 7.1B | 6.6B |
| Operating Income (EBIT) | 523.8M | 456.5M | 1.5B | 1.1B | 1.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 513.2M | 443.9M | 1.5B | 1.1B | 1.5B |
| Income Tax Expense | 183.6M | 216.5M | 356.1M | 283.1M | 332.9M |
| Bottom Line | |||||
| Net Income | 373.2M | 266.4M | 1.1B | 830.5M | 1.2B |
| Earnings from Cont. Ops | 329.6M | 227.3M | 1.1B | 817.2M | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 373.2M | 266.4M | 1.1B | 830.5M | 1.2B |
| Per Share | |||||
| Basic EPS | CN¥0.25 | CN¥0.18 | CN¥0.77 | CN¥0.57 | CN¥0.81 |
| Diluted EPS | CN¥0.25 | CN¥0.18 | CN¥0.77 | CN¥0.57 | CN¥0.80 |
| Revenue Per Share | CN¥5.71 | CN¥5.80 | CN¥6.57 | CN¥5.70 | CN¥5.73 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.4B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.4B |
| Profitability Metrics | |||||
| EBITDA | — | 1.5B | 2.4B | 1.9B | 2.2B |
| D&A | — | 1.0B | 932.6M | 789.6M | 659.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026